SG11201704942QA - Dengue virus vaccine compositions and methods of use thereof - Google Patents
Dengue virus vaccine compositions and methods of use thereofInfo
- Publication number
- SG11201704942QA SG11201704942QA SG11201704942QA SG11201704942QA SG11201704942QA SG 11201704942Q A SG11201704942Q A SG 11201704942QA SG 11201704942Q A SG11201704942Q A SG 11201704942QA SG 11201704942Q A SG11201704942Q A SG 11201704942QA SG 11201704942Q A SG11201704942Q A SG 11201704942QA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- dengue virus
- vaccine compositions
- virus vaccine
- compositions
- Prior art date
Links
- 229940023605 dengue virus vaccine Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095331P | 2014-12-22 | 2014-12-22 | |
| PCT/US2015/066549 WO2016106107A2 (en) | 2014-12-22 | 2015-12-18 | Dengue virus vaccine compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704942QA true SG11201704942QA (en) | 2017-07-28 |
Family
ID=56151628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704942QA SG11201704942QA (en) | 2014-12-22 | 2015-12-18 | Dengue virus vaccine compositions and methods of use thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10449243B2 (https=) |
| EP (1) | EP3236997B1 (https=) |
| JP (1) | JP2018502080A (https=) |
| CN (1) | CN106999568A (https=) |
| AU (1) | AU2015369875A1 (https=) |
| BR (1) | BR112017013270A2 (https=) |
| CL (1) | CL2017001595A1 (https=) |
| CO (1) | CO2017005830A2 (https=) |
| CR (1) | CR20170280A (https=) |
| ES (1) | ES2981476T3 (https=) |
| MX (1) | MX383329B (https=) |
| MY (1) | MY192543A (https=) |
| NI (1) | NI201700080A (https=) |
| PH (1) | PH12017501165B1 (https=) |
| SG (1) | SG11201704942QA (https=) |
| WO (1) | WO2016106107A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170143817A1 (en) * | 2015-11-20 | 2017-05-25 | Oregon Health & Science University | Dengue virus vaccine |
| TWI625393B (zh) * | 2016-11-15 | 2018-06-01 | 國立清華大學 | 對抗複數種登革熱病毒血清型之疫苗套組及其製備方法與用途 |
| WO2019112921A1 (en) | 2017-12-07 | 2019-06-13 | Merck Sharp & Dohme Corp. | Formulations of dengue virus vaccine compositions |
| WO2020236973A1 (en) * | 2019-05-20 | 2020-11-26 | Soligenix, Inc. | Compositions and methods of manufacturing trivalent filovirus vaccines |
| WO2025027616A1 (en) * | 2023-08-01 | 2025-02-06 | Serum Institute Of India Private Limited | Freeze-dried viral vaccine compositions and method of manufacturing thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US6190859B1 (en) | 1995-04-17 | 2001-02-20 | The United States Of America As Represented By The Secretary Of The Army | Method and kit for detection of dengue virus |
| US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
| WO1996040933A1 (en) | 1995-06-07 | 1996-12-19 | The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| EP0836090A1 (en) | 1996-10-12 | 1998-04-15 | Evotec BioSystems GmbH | Method of analysis of samples by determination of the distribution of specific brightnesses of particles |
| EP0977587B1 (en) | 1997-02-28 | 2005-06-15 | Acambis Inc. | Chimeric flavivirus vaccines |
| WO1999006068A2 (en) | 1997-07-31 | 1999-02-11 | Hawaii Biotechnology Group, Inc. | Recombinant dimeric envelope vaccine against flaviviral infection |
| AU774045B2 (en) | 1998-09-02 | 2004-06-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Dengue viruses that are replication defective in mosquitos for use as vaccines |
| EP1165127B1 (en) | 1999-03-26 | 2008-12-31 | Walter Reed Army Institute of Research | Multivalent dengue virus vaccine |
| US6537557B1 (en) | 1999-03-26 | 2003-03-25 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-4 virus vaccine |
| WO2000057909A2 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-2 virus vaccine |
| JP2002540169A (ja) | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | 弱毒化デング熱１型ウイルスワクチン |
| US6432411B1 (en) | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
| CA2966716C (en) | 2001-05-22 | 2019-11-26 | The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| KR101074175B1 (ko) | 2002-01-15 | 2011-10-14 | 사노피 파스테르 바이오로직스 씨오 | 플라비바이러스 백신 |
| ATE481982T1 (de) | 2002-05-03 | 2010-10-15 | Us Gov Health & Human Serv | Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2. |
| US20040259224A1 (en) | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
| US7189403B2 (en) | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
| CA2549173A1 (en) | 2003-12-08 | 2005-07-07 | Hybridon, Inc. | Modulation of immunostimulatory properties by small oligonucleotide-based compounds |
| SG156666A1 (en) | 2004-10-20 | 2009-11-26 | Acambis Inc | Vaccines against japanese encephalitis virus and west nile virus |
| CA2611954C (en) | 2005-06-17 | 2014-01-28 | Sanofi Pasteur | Dengue serotype 2 attenuated strain |
| CN101238144B (zh) | 2005-06-17 | 2012-09-05 | 赛诺菲巴斯德有限公司 | 登革血清型1减毒株 |
| CA2612047C (en) | 2005-06-24 | 2015-05-12 | Intervet International B.V. | Inactivated chimeric vaccines and related methods of use |
| CA2616026A1 (en) | 2005-07-22 | 2007-02-08 | Research Development Foundation | Attenuated strains of flaviviruses , and uses thereof |
| US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| AR061197A1 (es) | 2006-06-07 | 2008-08-13 | Sanofi Pasteur | Cepas del virus 3 del dengue vivas atenuadas |
| PL2589602T3 (pl) * | 2006-08-15 | 2016-11-30 | Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi | |
| FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| ES2517615T3 (es) | 2006-11-09 | 2014-11-03 | The United States Of America As Represented By The Secretary Of The Navy | Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo |
| US8440202B2 (en) | 2006-11-09 | 2013-05-14 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using the prime-boost approach |
| BRPI0904020B8 (pt) * | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
| AU2011367817B2 (en) * | 2010-10-29 | 2015-05-28 | Merck Sharp & Dohme Corp. | Recombinant subunit dengue virus vaccine |
| WO2012065105A2 (en) * | 2010-11-12 | 2012-05-18 | Thomas Monath | Chimeric flavivirus vaccines |
| AU2013295016A1 (en) * | 2012-07-24 | 2015-01-29 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| JP2016523251A (ja) * | 2013-06-21 | 2016-08-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | デングウイルスワクチン組成物およびその使用方法 |
-
2015
- 2015-12-18 ES ES15874179T patent/ES2981476T3/es active Active
- 2015-12-18 WO PCT/US2015/066549 patent/WO2016106107A2/en not_active Ceased
- 2015-12-18 EP EP15874179.3A patent/EP3236997B1/en active Active
- 2015-12-18 JP JP2017533387A patent/JP2018502080A/ja active Pending
- 2015-12-18 CN CN201580070223.8A patent/CN106999568A/zh active Pending
- 2015-12-18 MX MX2017008342A patent/MX383329B/es unknown
- 2015-12-18 CR CR20170280A patent/CR20170280A/es unknown
- 2015-12-18 BR BR112017013270A patent/BR112017013270A2/pt not_active Application Discontinuation
- 2015-12-18 AU AU2015369875A patent/AU2015369875A1/en not_active Abandoned
- 2015-12-18 PH PH1/2017/501165A patent/PH12017501165B1/en unknown
- 2015-12-18 SG SG11201704942QA patent/SG11201704942QA/en unknown
- 2015-12-18 US US15/536,319 patent/US10449243B2/en active Active
- 2015-12-18 MY MYPI2017000917A patent/MY192543A/en unknown
-
2017
- 2017-06-14 CO CONC2017/0005830A patent/CO2017005830A2/es unknown
- 2017-06-16 CL CL2017001595A patent/CL2017001595A1/es unknown
- 2017-06-20 NI NI201700080A patent/NI201700080A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3236997A4 (en) | 2018-05-30 |
| MX2017008342A (es) | 2017-10-24 |
| US10449243B2 (en) | 2019-10-22 |
| BR112017013270A2 (pt) | 2018-03-06 |
| ES2981476T3 (es) | 2024-10-09 |
| MY192543A (en) | 2022-08-26 |
| EP3236997A2 (en) | 2017-11-01 |
| CR20170280A (es) | 2017-08-21 |
| WO2016106107A3 (en) | 2016-08-18 |
| NI201700080A (es) | 2017-07-18 |
| US20170360917A1 (en) | 2017-12-21 |
| PH12017501165B1 (en) | 2023-02-22 |
| CL2017001595A1 (es) | 2018-01-26 |
| MX383329B (es) | 2025-03-13 |
| WO2016106107A2 (en) | 2016-06-30 |
| JP2018502080A (ja) | 2018-01-25 |
| AU2015369875A1 (en) | 2017-06-15 |
| EP3236997B1 (en) | 2024-05-29 |
| PH12017501165A1 (en) | 2017-12-11 |
| CO2017005830A2 (es) | 2017-08-31 |
| CN106999568A (zh) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257307B (en) | Transgenic crispr–cas9 preparations and methods of use | |
| ZA201700165B (en) | Influenza virus vaccines and uses thereof | |
| SG11201703569XA (en) | HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
| ZA201703163B (en) | Rna guided eradication of human jc virus and other polyomaviruses | |
| IL251834B1 (en) | Pharmaceutical compositions containing peptide variants and methods of using them | |
| IL250415B (en) | Antibodies against pd-l and methods of using them | |
| IL247309A0 (en) | Preparations for inhibiting virus replication and methods for their preparation and use | |
| HUE056172T2 (hu) | Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra | |
| SG11201606624WA (en) | Antibody moleules to dengue virus and uses thereof | |
| EP3092001A4 (en) | Immunomodulatory compositions and methods of use thereof | |
| SG11201610443WA (en) | Influenza virus vaccines and uses thereof | |
| ZA201701909B (en) | Trichoderma compositions and methods of use | |
| IL248160A0 (en) | Compositions of tissue fillers and methods of use | |
| SG11201708114SA (en) | Ophthalmic compositions and methods of use therefor | |
| SG10202004071UA (en) | Cryoprecipitate compositions and methods of preparation thereof | |
| IL259894A (en) | Improved compositions and improved methods for viral delivery of neoepitopes and their use | |
| SG11201702116VA (en) | Viral rna segments as immunomodulatory agents and vaccine components | |
| SG11201701256RA (en) | Vaccine compositions against dengue virus diseases | |
| EP3190886A4 (en) | Compositions and methods of use thereof | |
| SG11201703366RA (en) | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development | |
| SG11201510266SA (en) | Dengue virus vaccine compositions and methods of use thereof | |
| SG11201510617WA (en) | Methods and compositions for dengue virus vaccines | |
| SG11201704942QA (en) | Dengue virus vaccine compositions and methods of use thereof | |
| EP3169699A4 (en) | Cancer vaccine compositions and methods of use thereof | |
| EP3157950A4 (en) | Influenza vaccines and methods of use thereof |